Immuron Reveals New Award For Naval Medical Research Command And Walter Reed Army Institute Of Research To Advance Travelan; $2.3M Funding Is Approved By The U.S. Department of Defense

Author: Benzinga Newsdesk | August 16, 2024 06:05am

The focus of this new research agreement is to develop an enhanced formulation of Travelan potentially expanding the coverage of the product as a therapeutic measure against endemic military relevant diarrheal pathogens. This work will utilize the extensive experience of the US Department of Defense human infectious disease vaccine programs and will target key protective antigens of the major enteric bacterial pathogens Campylobacter, Shigella and Entertoxigenic E. coli strains not present in the current product formulation.

Posted In: IMRN